Regeneron drug for rare bone-growth disease earns FDA approval
Source Summary
Regeneron Pharmaceuticals has received FDA approval for a drug treating an ultra-rare disease characterized by abnormal bone formation in unintended locations.
Regeneron Pharmaceuticals has received FDA approval for a drug treating an ultra-rare disease characterized by abnormal bone formation in unintended locations.
